The record
Section 3505 of the Modernization of Cosmetics Regulation Act (Pub. L. 117-328) mandates an FDA rule on standardized asbestos testing for talc cosmetics; that statutory mandate survives FDA's withdrawal of its proposed rule (90 FR 54603).
Claim scope
That the testing mandate is statutory and remains in force notwithstanding the withdrawn 2024 proposal.
What this source does not establish
Advocacy characterizations that FDA is acting 'illegally' by withdrawing the rule (e.g., EWG statements) are advocacy positions, not legal conclusions — cite only the statute and the Federal Register withdrawal notice, never law-firm alerts.
Limitations
Keep the statutory obligation and the agency action as separate dated facts; make no deadline predictions.
Source
Federal Register — 89 FR 105490 (Dec. 27, 2024), FR Doc. 2024-30544; 90 FR 54603 (Nov. 28, 2025), FR Doc. 2025-21407; MoCRA sec. 3505, Pub. L. 117-328, 136 Stat. 4459